GotoPER - Physicians' Education Resource
Back to Home
Video

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Create AccountAlready Registered? Login Here

Release Date

December 19, 2025

Expiration Date

January 28, 2026

Credits

1.5 CME, NCPD

Specialties

Breast Cancer, Medical Oncology+3 more

Release Date: December 19, 2025

Expiration Date: January 27, 2026

Activity Overview

This educational activity is an archive of the live presentation held on Thursday, December 11, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is primarily directed toward medical oncologists, advanced practice providers, oncology nurses, and other health care professionals involved in the diagnosis and management of patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Summarize key characteristics of ESR1 mutations in HR+/HER2- metastatic breast cancer (MBC), including incidence, timing, and impact on treatment efficacy
  • Discuss novel therapeutic strategies for targeting the estrogen receptor signaling pathway that have driven the development of next-generation endocrine therapies
  • Evaluate safety and efficacy data from recent clinical trials of emerging next-generation endocrine therapies
  • Apply new evidence and guideline recommendations to make individualized treatment plans for patients with HR+/HER2- MBC
Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.


Acknowledgment of Commercial Support

This activity is supported by educational grants from Arvinas and Pfizer, Inc.

Related Content

View All

Course

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Create Account